Evidence map›Paper›PMID 40221571›Full record

ArticleScientific reports2025

Deep learning-based identification of patients at increased risk of cancer using routine laboratory markers.

Vivek Singh, Shikha Chaganti, Matthias Siebert, Sowmya Rajesh, Andrei Puiu, Raj Gopalan, Jamie Gramz, Dorin Comaniciu, Ali Kamen

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vivek SinghSiemens Healthineers, Digital Technology and Innovation, Princeton, 08540, USA. vivek-singh@siemens-healthineers.com.
Shikha ChagantiSiemens Healthineers, Digital Technology and Innovation, Princeton, 08540, USA.
Matthias SiebertSiemens Healthineers, Digital Technology and Innovation, 91052, Erlangen, Germany.
Sowmya RajeshSiemens Healthineers, Digital Technology and Innovation, Princeton, 08540, USA.
Andrei PuiuSiemens SRL, Advanta, 500007, Brasov, Romania.
Raj GopalanSiemens Healthineers, Laboratory Diagnostics, Tarrytown, NY, 10591, USA.
Jamie GramzSiemens Healthineers, Digital and Automation, Malvern, PA, 19355, USA.
Dorin ComaniciuSiemens Healthineers, Digital Technology and Innovation, Princeton, 08540, USA.
Ali KamenSiemens Healthineers, Digital Technology and Innovation, Princeton, 08540, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early screening for cancer has proven to improve the survival rate and spare patients from intensive and costly treatments due to late diagnosis. Cancer screening in the healthy population involves an initial risk stratification step to determine the screening method and frequency, primarily to optimize resource allocation by targeting screening towards individuals who draw most benefit. For most screening programs, age and clinical risk factors such as family history are part of the initial risk stratification algorithm. In this paper, we focus on developing a blood marker-based risk stratification approach, which could be used to identify patients with elevated cancer risk to be encouraged for taking a diagnostic test or participate in a screening program. We demonstrate that the combination of simple, widely available blood tests, such as complete blood count and complete metabolic panel, could potentially be used to identify patients at risk for colorectal, liver, and lung cancers with areas under the ROC curve of 0.76, 0.85, 0.78, respectively. Furthermore, we hypothesize that such an approach could not only be used as pre-screening risk assessment for individuals but also as population health management tool, for example to better interrogate the cancer risk in certain sub-populations.

Indexed as

Biomarkers, TumorDeep LearningEarly Detection of CancerNeoplasmsAgedAlgorithmsFemaleHumansMaleMiddle AgedRisk AssessmentRisk FactorsROC CurveBiomarkers, TumorDeep learningLaboratory markersOncology screening

Identifiers

PMID40221571
PMCPMC11993759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.